Germark Biotechnology

Germark Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes its proprietary G-Link platform, a site-specific conjugation technology that leverages glycan engineering to produce highly stable and homogeneous ADC candidates. Germark's lead program, GM-101, is a Claudin 18.2-targeted ADC currently in Phase 1/2 clinical trials for the treatment of gastric and pancreatic cancers. By focusing on improved therapeutic indices and reduced off-target toxicity, the company aims to address significant unmet needs in the treatment of refractory solid tumors. Germark's pipeline also includes programs targeting HER2 and other validated tumor antigens using their specialized linker-payload systems.